<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280289</url>
  </required_header>
  <id_info>
    <org_study_id>CBD Study 1</org_study_id>
    <nct_id>NCT04280289</nct_id>
  </id_info>
  <brief_title>CBD Cannabis Extract: Pharmacokinetic Studies</brief_title>
  <official_title>CBD Cannabis Extract: Pharmacokinetic Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi, Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi, Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The initial goal is to ascertain the pharmacokinetic (PK) profile of CBD (cannabidiol) after
      a single dose of CBDE (cannabidiol extract), although the plan is to extend these studies to
      multiple dose administrations in the future, since it is likely that (cannabidiol) and/or its
      metabolites will show some accumulation. These studies will provide detailed information that
      will inform the continuation and expansion of CBDE in other research projects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to determine the PK profile of CBD(cannabidiol) , its metabolites, and minor
      phytocannabinoids after single dose administration of CBDE (at 2.5 mg/kg CBD). Attainment of
      this goal will provide essential information on phytocannabinoid disposition and dosing
      regimen optimization. To accomplish this objective, the working hypothesis that complex
      phytochemical mixtures present in full spectrum hemp extracts (FSHEs), as exemplified by
      CBDE, differ from purified CBD-containing products with regard to PK, will be tested. The
      approach to testing this working hypothesis will be to use liquid chromatography-mass
      spectrometry (LC/MS) to both characterize the phytocannabinoid concentration-time profiles
      following CBDE administration (single and multiple dosing).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is a single center, prospective, Phase I PK trial. A total of 10 healthy subjects will be enrolled into the study. This study will evaluate the pharmacokinetics of CBDE.
The PK of CBD, 9-tetrahydrocannabinol (THC) and their principal metabolites will be determined after a single CBDE dose delivering 2.5 mg/kg CBD. ). CBDE will be provided in liquid concentration of 50mg/ml in sesame seed oil (SSO).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of minor phytocannabinoids, and metabolites following single dose administration of Cannabis extract (CBDE) (at 2.5 mg/kg cannabidiol (CBD).</measure>
    <time_frame>0- 72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of minor phytocannabinoids, and metabolites following single dose administration of Cannabis extract (CBDE) (at 2.5 mg/kg cannabidiol (CBD).</measure>
    <time_frame>0- 72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area-under-the-concentration-time profiles (AUC), and area-under-the moment curve (AUMC), for CBD (cannabidiol) , up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl/F) up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd),up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vdss),up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (ke), half-life (t1/2), up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT), up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax), up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax), up to 72 hours after Cannabis extract administration.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of Cannabis extract in normal human volunteers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Cannabidiol extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 healthy subjects (5 female, 5 male), will be enrolled into the study. Each subject will receive a single CBDE dose delivering 2.5 mg/kg CBD, after consumption of a standardized meal.
Nine (9mL) of blood for PK analysis, at each of the following timepoints: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the study drug administration.
Urine will be collected at the following timepoints: Predose, 0-4 hrs, 4-8 hrs, 8-12 hrs, 12-24 hrs, 24-36 hrs, 36-48 hrs, and 48-72 hrs for PK analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cannabidiol extract</intervention_name>
    <description>The test article &quot;CBD Cannabis Extract Oral Solution&quot; will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Î”9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials</description>
    <arm_group_label>Cannabidiol extract</arm_group_label>
    <other_name>cannabidiol, CBD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal, healthy adults aged 21 to 55 years

        Exclusion Criteria:

          -  Allergy to sesame oil/products

               -  Obese: BMI is 35 or higher

               -  Smoker (tobacco &amp; marijuana use [smoking or use of oral hemp/CBD products])

               -  Currently any taking prescriptions medication(s) [with exception of oral
                  contraceptives] or over-the-counter medications/supplements

               -  Consuming botanical/non-botanical dietary supplements (3 days prior to study)

               -  Known history of cardiac, liver, kidney or hematological disease, diabetes

               -  Autoimmune disorders

               -  Known history of Neurologic/Psychiatric disorders

               -  Report of an active infection

               -  Subject is pregnant or breast-feeding, or is expecting to conceive during the
                  study

               -  Subjects of child bearing potential will use (or is currently using) during the
                  study, one of the following acceptable methods of contraception:

        Male sterilization (vasectomy) Female sterilization (tubal ligation, hysterectomy)
        Intrauterine service intrauterine device (IUD) or other implant Oral contraceptive,
        injectable contraceptive Contraceptive patch/ring Diaphragm Male condom Sponge/spermicide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bill Gurley, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Scientist, National Center for Natural Products Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bill Gurley, Ph. D.</last_name>
    <phone>662-915-7130</phone>
    <email>bjgurley@olemiss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerri Harrison</last_name>
    <phone>662-915-2103</phone>
    <email>kaharri6@olemiss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>University</city>
        <state>Mississippi</state>
        <zip>38677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.fda.gov/media/128592/download</url>
    <description>US FDA Hearing on Cannabis-Derived Compounds and Products</description>
  </link>
  <reference>
    <citation>Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy Behav. 2017 May;70(Pt B):355-363. doi: 10.1016/j.yebeh.2017.01.031. Epub 2017 Feb 23. Review.</citation>
    <PMID>28237318</PMID>
  </reference>
  <results_reference>
    <citation>Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017 Nov 7;318(17):1708-1709. doi: 10.1001/jama.2017.11909.</citation>
    <PMID>29114823</PMID>
  </results_reference>
  <results_reference>
    <citation>Borchardt D. Hemp cannabis product sales projected to hit $1 billion in 3 years. Forbes 2017, August, 23.</citation>
  </results_reference>
  <results_reference>
    <citation>Carvalho RK, Andersen ML, Mazaro-Costa R. The effects of cannabidiol on male reproductive system: A literature review. J Appl Toxicol. 2020 Jan;40(1):132-150. doi: 10.1002/jat.3831. Epub 2019 Jul 17. Review.</citation>
    <PMID>31313338</PMID>
  </results_reference>
  <results_reference>
    <citation>Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Erratum in: Lancet Neurol. 2016 Apr;15(4):352.</citation>
    <PMID>26724101</PMID>
  </results_reference>
  <results_reference>
    <citation>Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618.</citation>
    <PMID>28538134</PMID>
  </results_reference>
  <results_reference>
    <citation>Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.</citation>
    <PMID>29540584</PMID>
  </results_reference>
  <results_reference>
    <citation>Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, ElSohly MA, Gurley BJ, Koturbash I. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Molecules. 2019 Apr 30;24(9). pii: E1694. doi: 10.3390/molecules24091694.</citation>
    <PMID>31052254</PMID>
  </results_reference>
  <results_reference>
    <citation>Ewing LE, McGill MR, Yee EU, Quick CM, Skinner CM, Kennon-McGill S, Clemens M, Vazquez JH, McCullough SS, Williams DK, Kutanzi KR, Walker LA, ElSohly MA, James LP, Gurley BJ, Koturbash I. Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration. Molecules. 2019 Jun 17;24(12). pii: E2256. doi: 10.3390/molecules24122256.</citation>
    <PMID>31212965</PMID>
  </results_reference>
  <results_reference>
    <citation>Foster BC, Abramovici H, Harris CS. Cannabis and Cannabinoids: Kinetics and Interactions. Am J Med. 2019 Nov;132(11):1266-1270. doi: 10.1016/j.amjmed.2019.05.017. Epub 2019 May 30. Review.</citation>
    <PMID>31152723</PMID>
  </results_reference>
  <results_reference>
    <citation>Grof CPL. Cannabis, from plant to pill. Br J Clin Pharmacol. 2018 Nov;84(11):2463-2467. doi: 10.1111/bcp.13618. Epub 2018 May 24. Review.</citation>
    <PMID>29701252</PMID>
  </results_reference>
  <results_reference>
    <citation>(Harvey et al; Ujvary and Hanus; Jiang et al; Huestis, etc.1999): CBD is a potent inhibitor of CYP450 isozymes, primarily CYP2C and CYP3A isoforms, in in vitro and animal models</citation>
  </results_reference>
  <results_reference>
    <citation>Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, BusardÃ² FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Review.</citation>
    <PMID>31161980</PMID>
  </results_reference>
  <results_reference>
    <citation>H.R.2 - Agriculture Improvement Act of 2018, Public Law No: 115-334, Dec. 20, 2018.</citation>
  </results_reference>
  <results_reference>
    <citation>McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC 3rd. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018 Aug 1;5(9):1077-1088. doi: 10.1002/acn3.621. eCollection 2018 Sep.</citation>
    <PMID>30250864</PMID>
  </results_reference>
  <results_reference>
    <citation>Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1009-1031. doi: 10.1002/cpdd.665. Epub 2019 Feb 21.</citation>
    <PMID>30791225</PMID>
  </results_reference>
  <results_reference>
    <citation>Pamplona FA, da Silva LR, Coan AC. Corrigendum: Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol. 2019 Jan 10;9:1050. doi: 10.3389/fneur.2018.01050. eCollection 2018.</citation>
    <PMID>30687209</PMID>
  </results_reference>
  <results_reference>
    <citation>Personal statement from principal investigator, Dr. John Ingram, Dept. of Pediatrics, University of Mississippi Medical Center on his experience with &quot;Cannabidiol (CBD) Cannabis Extract Oral Solution for Drug Resistant Pediatric Epilepsy (Compassionate Use),&quot; April 18, 2018.</citation>
  </results_reference>
  <results_reference>
    <citation>Purohit V, Rapaka R, Shurtleff D. Role of cannabinoids in the development of fatty liver (steatosis). AAPS J. 2010 Jun;12(2):233-7. doi: 10.1208/s12248-010-9178-0. Epub 2010 Mar 5. Review.</citation>
    <PMID>20204561</PMID>
  </results_reference>
  <results_reference>
    <citation>Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol Sci. 2016 Jul;37(7):594-605. doi: 10.1016/j.tips.2016.04.005. Epub 2016 May 11. Review.</citation>
    <PMID>27179600</PMID>
  </results_reference>
  <results_reference>
    <citation>Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344-64. doi: 10.1111/j.1476-5381.2011.01238.x. Review.</citation>
    <PMID>21749363</PMID>
  </results_reference>
  <results_reference>
    <citation>Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018 Oct;87:131-136. doi: 10.1016/j.yebeh.2018.07.020. Epub 2018 Aug 9.</citation>
    <PMID>30100226</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs. 2018 Nov;32(11):1053-1067. doi: 10.1007/s40263-018-0578-5. Erratum in: CNS Drugs. 2019 Apr;33(4):397.</citation>
    <PMID>30374683</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor L, Crockett J, Tayo B, Morrison G. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. J Clin Pharmacol. 2019 Aug;59(8):1110-1119. doi: 10.1002/jcph.1412. Epub 2019 Mar 28.</citation>
    <PMID>30921490</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.</citation>
    <PMID>26800377</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang YH, Avula B, ElSohly MA, Radwan MM, Wang M, Wanas AS, Mehmedic Z, Khan IA. Quantitative Determination of Î”9-THC, CBG, CBD, Their Acid Precursors and Five Other Neutral Cannabinoids by UHPLC-UV-MS. Planta Med. 2018 Mar;84(4):260-266. doi: 10.1055/s-0043-124873. Epub 2017 Dec 20.</citation>
    <PMID>29262425</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>cannabidiol extract</keyword>
  <keyword>cannabidiol</keyword>
  <keyword>CBDE</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

